GRACE FITZPATRICK: Open Payments
NPI 1245782010 · COLUMBIA, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,461 in 121 payments from 20 companies in 2025. Trend: 2023 $2,471 · 2024 $2,804 · 2025 $2,461
Food & beverage: $2,384Education: $77
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 27 | $470 |
| Janssen Biotech, Inc. | 15 | $410 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 10 | $227 |
| PFIZER INC. | 16 | $197 |
| Regeneron Healthcare Solutions, Inc. | 7 | $161 |
| Madrigal Pharmaceuticals | 6 | $142 |
| GENZYME CORPORATION | 5 | $136 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $123 |
| Gilead Sciences, Inc. | 4 | $97 |
| Lilly USA, LLC | 3 | $95 |
Products named: TREMFYA, DUPIXENT, XIFAXAN, RINVOQ, REZDIFFRA, SKYRIZI, XELJANZ, LINZESS.
Industry payments across MD — which companies pay providers there.
